Sharps Technology (STSS) investor relations material

Company overview and business model

• Operates as a medical device sales and distribution enterprise focused on syringes and drug-delivery systems, with plans to expand by representing third-party manufacturers of complementary medical products.

• Recently adopted a digital asset treasury strategy centered on accumulating Solana (SOL) to generate on-chain yield and support long-term growth.

• Settled outstanding litigation and spun off its Hungarian subsidiary, transferring related assets and IP.

Financial performance and metrics

• Closed a $400 million PIPE financing, using proceeds to purchase over 2,000,000 SOL, which now comprise the majority of treasury assets.

• May receive up to $614.8 million in gross proceeds if all warrants in the offering are exercised.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders, but will receive proceeds from warrant exercises, intended for general corporate purposes, debt repayment, share repurchases, working capital, capital expenditures, and further SOL purchases.

• Proceeds may also fund acquisitions of businesses, assets, or technologies that complement current operations.